| Efficacy and safety evaluation of loreclezole as add-on treatment in therapy-resistant epilepsy patients. | |
| | |
MedLine Citation:
|
PMID: 2065645 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Thirteen drug-resistant epilepsy patients received loreclezole as add-on therapy. The trial lasted 6 months. Loreclezole was dosed to reach a target plasma concentration between 1 and 3 mg/l. The seizure frequency in the total group decreased by 23%. A reduction of 50% or more was observed in four patients. These effects are most likely related to loreclezole, as doses and plasma levels of the associated anti-epileptic drugs remained unchanged during the study. Loreclezole was tolerated well and no changes in haematological or biochemical parameters were observed. |
| | |
Authors:
|
T Rentmeester; J Hulsman |
Related Documents
:
|
10614035 - Electroconvulsive therapy and subdural hemorrhage. 18157025 - Perioperative complications of blood brain barrier disruption under general anesthesia:... 11709645 - Vagus nerve stimulation: clinical experience in a large patient series. 10604605 - Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. 22364895 - Residual valve and stricture after posterior urethral valve ablation: how to evaluate? 16336605 - Endoscopic and histologic evaluation of advanced megaesophagus after esophagocardioplas... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Epilepsy research Volume: 8 ISSN: 0920-1211 ISO Abbreviation: Epilepsy Res. Publication Date: 1991 Mar |
Date Detail:
|
Created Date: 1991-08-12 Completed Date: 1991-08-12 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8703089 Medline TA: Epilepsy Res Country: NETHERLANDS |
Other Details:
|
Languages: eng Pagination: 166-9 Citation Subset: IM |
Affiliation:
|
Epilepsy Centre Kempenhaeghe, Heeze, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anticonvulsants / adverse effects, therapeutic use* Drug Resistance Drug Therapy, Combination Epilepsy / drug therapy*, physiopathology Female Humans Male Middle Aged Triazoles / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Anticonvulsants; 0/Triazoles; 117857-45-1/loreclezole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Temporal distribution of seizures in epilepsy.
Next Document: The role of technical, biological and pharmacological factors in the laboratory evaluation of antico...